Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.42 |
| ▸ | PPARG | P37231 | 13/20 | 0.42 |
| ▸ | PPARD | Q03181 | 13/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417573 | 0.87 | PPARA (0.43) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL29306632 | 0.84 | PPARA (0.51) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL14988854 | 0.81 | PPARA (0.55) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL5472572 | 0.81 | PPARA (0.40) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL1417528 | 0.80 | PPARA (0.49) | PPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL12670978 | 0.80 | CNR1 (0.33) | MEN1KMT2A | |
| SCHEMBL7994922 | 0.79 | KDM4E (0.49) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL31426784 | 0.78 | ALDH1A1 (0.45) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL12329622 | 0.75 | PPARA (0.46) | PPARAPPARGPPARDMEN1CYP1A2 | |
| SCHEMBL659617 | 0.75 | PPARA (0.53) | PPARAPPARGPPARDMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | PPARA 455/4885PPARG 396/4885PPARD 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.